The company’s angel investor is Professor Brendan Lee, an academician of the American Academy of Sciences and the chair of the Department of Genetics at Baylor College of Medicine.

It is reported that “Jinfeng Biology” has recently completed $10 million Pre-A round of financing. The investors in this round of financing are mainly Hanyi Capital and Hongli Venture Capital. The funds raised will be mainly used for the upgrade of the “Jinfeng Bio” technology platform, the construction of the patent pool and the construction of related teams.

“Jingfeng Bio” is a tumor cell therapy product developer, committed to the research and development and application of precision cell therapy combined with non-invasive tumor detection and screening, and the use of biological information technology and artificial intelligence technology to deeply explore tumor multi-omics Data, optimize cell therapy strategies, and improve the effectiveness of tumor treatment. The company’s angel investor is Professor Brendan Lee, an academician of the American Academy of Sciences and the head of the Department of Genetics at Baylor College of Medicine. Currently, Professor Brendan Lee is also serving as the scientific consultant of “Jianfeng Biology”.

Picture from Pixabay

The core technology of “Jinfeng Bio” is tumor infiltrating lymphocyte (TIL), a new type of anti-tumor effector cell. Unlike ordinary immune cells, TIL immune cells are derived from tumor tissues, which determines that the screened TILs have a strong ability to recognize tumor-associated antigens, and can accurately migrate to the tumor in situ after being amplified in vitro and transfused into patients. Effectively kill tumor cells.

“Jianfeng Bio” TILs therapy first uses bioinformatics and AI technology to assist gene sequencing technology to determine the specific mutation information in the patient’s tumor cells, and then uses the mutation information to find the T cells that can most effectively target these mutations, and finally extract the rich Collect these T cells to achieve the purpose of accurately identifying and killing tumor cells. According to the introduction, this therapy is safer than CAR-T cell therapy and has a broad future development track. “Lung cancer, non-small cell carcinoma, colorectal cancer, Breast cancer and cervical cancer are the directions that TILs therapy is trying to overcome.”

Fei Fuli Yu, the founder and CEO of “Jinfeng Bio”, graduated from Baylor College of Medicine, under the tutelage of RiProfessor Chard Gibbs also obtained a Ph.D. in molecular genetics. After graduation, he completed his postdoctoral research work with Professor David Reich, a population geneticist and ancient human geneticist at Harvard Medical School. Since then, he has worked in the Human Genome Sequencing Center of the Department of Genetics, Baylor College of Medicine, where he participated in and led many major international human genome projects; he also served as a shellfishRuiji is the company’s chief information officer, who is mainly responsible for overall bioinformatics analysis, product development and cloud computing technology artificial intelligence technology in genomics.

The founding team also includes bioinformatics statistics experts in the field of tumor multi-omics research, well-known pharmaceutical companies in the field of cell therapy, and cell experts with rich first-line practical experience in R&D and preparation and clinical applications. Yu Fuli said: “I hope that our products can integrate genetic testing, cooperate with upstream companies that do second-generation sequencing technology, and closely contact downstream companies that research cell therapy products, and go to the clinical treatment side to produce a complete Products.”

Editor: Cai Shuning